Answers are grounded in this paper and cite their sources.
To the Editor: Ulcerative colitis (UC) associated with primary sclerosing cholangitis (UC-PSC) is considered a separate entity than UC alone. It typically presents as pancolitis with rectal sparing and backwash ileitis, and active endoscopic disease is often clinically silent. Our group and others have shown that up to one-third of patients with UC-PSC have exacerbation of their colitis after liver transplant (LT) despite intense immunosuppression1. Thus, it is reasonable to expect that UC-PSC, with its distinct genetic and immunopathology, would respond to different therapeutic approaches than UC alone. Small studies have evaluated the role of oral vancomycin (OV) in the treatment of PSC in children with inflammatory bowel disease (IBD) and have shown that vancomycin improves liver function tests and biliary imaging2,3. To the best of our knowledge, the role of OV in the treatment of UC in UC-PSC adult patients has not yet been evaluated. A retrospective chart review was done of 8 UC-PSC patients seen in our IBD clinic and who were placed on OV for symptomatic UC. Average disease duration was 15 years, and 5 patients had LT for PSC. Patients had previously failed, were intolerant to, or only had partial response to mesalamine (7), immunomodulators (5), and/or 1 or more biologics (5). Patients were started on OV at 125 mg PO QID for 6–8 weeks and then tapered down to the lowest effective dose of 125 mg PO TID or BID (Table 1). Total Mayo score before OV ranged from 6 to 11, with endoscopic subscores of 2. Total Mayo score 6–12 months after OV ranged from 0 to 2, with an endoscopic subscore of 0–1 and a total drop in Mayo score of 5–11 points (average reduction in Mayo Score was 7 points). Duration of follow-up was 9–36 months, and all patients maintained clinical and endoscopic response/remission; no side effects to OV were noted. Our studies suggest that OV is a potentially effective therapy for the induction and maintenance of remission of UC in the subset of patients with UC-PSC, including those with longstanding disease. This therapy is easy to take, low cost, and safe and does not add to the systemic immunosuppression of post-LT patients. Oral Vancomycin Effects on Clinical and Endoscopic UC Mayo Score Abbreviations: 5-ASA, 5-aminosalicylate; 6-MP, 6-mercaptopurine. Oral Vancomycin Effects on Clinical and Endoscopic UC Mayo Score Abbreviations: 5-ASA, 5-aminosalicylate; 6-MP, 6-mercaptopurine. Supported by: There are no sources of support that require acknowledgment and no disclosures of funding received for this work.
No takes yet. Share an insight, caveat, or question.
Dao et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: